NetScientific PLC ProAxsis to Present New Data at ATS 2018
May 02 2018 - 2:01AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
02 May 2018
NetScientific plc
("NetScientific" or the "Company" or the "Group")
ProAxsis to Present New Data Underscoring the Importance of
Neutrophil Elastase in COPD at ATS 2018
London, UK - May 2(nd) 2018 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation group, announces an update for its portfolio
company, ProAxsis.
ProAxsis will be presenting data on NEATstik(R), its novel point
of care test for monitoring active neutrophil elastase (NE) in
chronic respiratory disease. The data demonstrated that NEATstik(R)
can identify patients with elevated active NE concentrations which
could be related to bacterial infections which lead to respiratory
diseases.
ProAxsis will also present data on a new high sensitivity
version of the assay to a US audience at the annual American
Thoracic Society conference. The development of the newer assay,
which was co-funded by Innovate UK, provides further validation and
underscores the emerging importance of neutrophil elastase as a
leading indicator of infection and inflammation in patients with
Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD)
and bronchiectasis, and an important drug target.
Commenting on the news, Francois Martelet, Chief Executive
Officer of NetScientific and Chairman of ProAxsis said: "The data
presented at ATS show that NEATstik(R) can play a role in
identifying the role played by a bacterial infection in COPD. We
are very pleased to see continued validation of the role of
neutrophil elastase in respiratory diseases, and excited about
presenting data at the prestigious ATS Annual Conference. We would
also like to thank Innovate UK for helping ProAxsis to advance both
scientifically and commercially, and look forward to collaborating
again in the future."
The full text of the announcement from ProAxsis can be found
below.
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite,
CFO
Consilium Strategic
Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / netscientific@consilium-comms.com
Jessica Hodgson /
Chris Welsh / Laura
Thornton
Stifel Nicolaus Europe Tel: +44 (0) 20 7710 7600
Limited (NOMAD and Broker)
Jonathan Senior / David
Arch / Ben Maddison
ProAxsis Presenting New Data on NEATstik and New High
Sensitivity Neutrophil Elastase Immunoassay at ATS 2018
Date: May 2, 2018
ProAxsis confirms that new data on its ProteaseTag(R) technology
will be presented at the American Thoracic Society Conference,
which takes place between May 19th-24th in San Diego.
The University of Oxford team will be presenting data on
NEATstik(R), a novel point-of-care test for monitoring active
neutrophil elastase in chronic diseases such as COPD, to the US
respiratory community for the first time. NEATstik(R) gives a
qualitative result from sputum in 10 minutes with minimal
processing. The authors assessed 39 sputum samples and concluded
that NEATstik(R) has the potential to identify those patients with
elevated active NE concentrations which could be related to
bacterial infection in patients with airways disease.
In addition, the company will be presenting data for the first
time on the new, high sensitivity version of its immunoassay for
measuring active neutrophil elastase. This immunoassay was
developed in recognition of the fact that many researchers are
seeking to measure biomarkers in respiratory fluids other than
sputum, where the activity levels may be significantly lower. The
assay development was co-funded by the UK's innovation agency,
Innovate UK.
Details of these two presentations can be found below:
EVALUATING THE SENSITIVITY AND SPECIFICITY OF NEATSTIK(R)
TECHNOLOGY COMPARED TO AN ACTIVITY-BASED IMMUNOASSAY IN SPUTUM
SAMPLES.
Presented by Professor Mona Bafhadhel, University of Oxford
AUGMENTATION OF PROTEASETAG(R) ACTIVE NEUTROPHIL ELASTASE
IMMUNOASSAY SENSITIVITY
Presented by Dr Darragh McCafferty, ProAxsis Limited
Dr David Ribeiro, CEO of ProAxsis, said: "NEATstik(R) was
registered with a European CE Mark in late 2017, and we're
delighted that the Oxford team will now be introducing initial data
on the product to a US audience for the first time. We're very
grateful to Innovate UK for supporting the development of a new
version of our Active Neutrophil Elastase Immunoassay, and look
forward to making this product commercially available in the near
future."
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
About ProAxsis Limited:
ProAxsis is developing a range of products for the capture,
detection and measurement of active protease biomarkers of disease.
Its first commercialised immunoassay measures neutrophil elastase,
a leading indicator of infection and inflammation in patients with
Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD)
and bronchiectasis, and an important drug target. The rapid and
easy-to-use tests being developed by ProAxsis incorporate patented
ProteaseTags(R); smart molecules which trap an active protease
within a complex biological sample and enable a visual readout of
its presence. ProteaseTags(R) provide a unique tool to identify and
quantify active protease biomarkers and will assist in the clinical
validation of new therapeutics.
ProAxsis is part of the NetScientific Group and is one of the
Group's core portfolio companies. The company is also supported by
QUBIS, the commercialisation arm of Queens University. To find out
how ProAxsis can support the measurement of active protease
biomarkers of disease, or for any further queries, please contact
info@proaxsis.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAMMGGKDMRGRZM
(END) Dow Jones Newswires
May 02, 2018 02:01 ET (06:01 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024